HYDROMORPHONE HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for hydromorphone hydrochloride and what is the scope of freedom to operate?
Hydromorphone hydrochloride
is the generic ingredient in five branded drugs marketed by Purdue Pharma Lp, Fresenius Kabi Usa, Barr, Hikma, Hospira, Hospira Inc, Rising, Watson Labs, Rhodes Pharms, Ascent Pharms Inc, Chartwell, Specgx Llc, Actavis Labs Fl Inc, Osmotica Pharm Us, Padagis Us, Aurolife Pharma Llc, Nesher Pharms, and Nostrum Labs Inc, and is included in twenty-nine NDAs. There are two patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Hydromorphone hydrochloride has twenty-two patent family members in twelve countries.
There are nine drug master file entries for hydromorphone hydrochloride. Seventeen suppliers are listed for this compound.
Summary for HYDROMORPHONE HYDROCHLORIDE
International Patents: | 22 |
US Patents: | 2 |
Tradenames: | 5 |
Applicants: | 18 |
NDAs: | 29 |
Drug Master File Entries: | 9 |
Finished Product Suppliers / Packagers: | 17 |
Raw Ingredient (Bulk) Api Vendors: | 26 |
Clinical Trials: | 303 |
Patent Applications: | 2,708 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for HYDROMORPHONE HYDROCHLORIDE |
What excipients (inactive ingredients) are in HYDROMORPHONE HYDROCHLORIDE? | HYDROMORPHONE HYDROCHLORIDE excipients list |
DailyMed Link: | HYDROMORPHONE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for HYDROMORPHONE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Cure Addiction Now | Phase 3 |
Johns Hopkins University | Phase 3 |
University of Miami | Phase 2 |
Pharmacology for HYDROMORPHONE HYDROCHLORIDE
Drug Class | Opioid Agonist |
Mechanism of Action | Full Opioid Agonists |
Medical Subject Heading (MeSH) Categories for HYDROMORPHONE HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for HYDROMORPHONE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for HYDROMORPHONE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
DILAUDID-HP | Injection | hydromorphone hydrochloride | 0.2 mg/mL | 019034 | 1 | 2023-12-19 |
DILAUDID-HP | Injection | hydromorphone hydrochloride | 0.5 mg/0.5 mL and 1 mg/mL | 019034 | 1 | 2022-12-13 |
DILAUDID | Tablets | hydromorphone hydrochloride | 2 mg, 4 mg, and 8 mg | 019892 | 1 | 2013-08-05 |
DILAUDID-HP | Injection | hydromorphone hydrochloride | 10 mg/mL | 019034 | 1 | 2011-11-04 |
DILAUDID-HP | Injection | hydromorphone hydrochloride | 2 mg/mL | 019034 | 1 | 2011-06-22 |
DILAUDID | Oral Solution | hydromorphone hydrochloride | 5 mg/5mL | 019891 | 1 | 2011-02-25 |
EXALGO | Extended-release Tablets | hydromorphone hydrochloride | 8 mg and 12 mg | 021217 | 1 | 2010-09-02 |
EXALGO | Extended-release Tablets | hydromorphone hydrochloride | 16 mg | 021217 | 1 | 2010-08-02 |
US Patents and Regulatory Information for HYDROMORPHONE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fresenius Kabi Usa | DILAUDID | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-003 | Apr 30, 2009 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Nesher Pharms | HYDROMORPHONE HYDROCHLORIDE | hydromorphone hydrochloride | TABLET;ORAL | 077311-003 | Nov 9, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Specgx Llc | EXALGO | hydromorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021217-004 | Aug 24, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HYDROMORPHONE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Rhodes Pharms | DILAUDID | hydromorphone hydrochloride | TABLET;ORAL | 019892-002 | Nov 9, 2007 | ⤷ Sign Up | ⤷ Sign Up |
Fresenius Kabi Usa | DILAUDID-HP | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-001 | Jan 11, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Specgx Llc | EXALGO | hydromorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021217-004 | Aug 24, 2012 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for HYDROMORPHONE HYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 204798475 | ⤷ Sign Up | |
China | 104528165 | Packaging system for oxygen-sensitive drugs | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2014140097 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.